Some joint symptoms need an exam before a planned PRP treatment

Heat, fever and sudden weakness need prompt attention

Fever with a hot, badly swollen joint may signal a serious illness. Being unable to stand after a fall, twist or hard blow requires a quick exam.

Contact the clinic promptly if redness spreads or warmth worsens after a joint procedure. Sudden numbness, lost strength or trouble controlling the bladder needs urgent care.

Mention any recent illness or joint procedure during the exam. Ask who takes calls if a problem starts after the office closes.

The visit checks the joint, medicines and health history

Describe how the soreness started while the clinician checks the joint’s motion. Bring any X-ray and write down every medicine you take.

Blood thinners and some health problems can affect the safety of a procedure. Don’t alter prescribed medicine without approval from the clinician responsible for it.

The exam may also check strength, swelling and the painful movement. Those findings help rule out a tear or illness before planned PRP care.

Most joint PRP care is paid fully by the patient

Most people cover the entire clinic charge themselves for joint or tendon PRP. That doesn’t mean bringing cash; it means insurance usually won’t pay the bill.

Medicare’s national policy pays for PRP only when certain lasting wounds are studied under an approved program. It doesn’t provide national coverage for arthritis or lasting tendon soreness.

Ask your health plan and the clinic to confirm the current rules. Get a written price that says which visits and follow-up are included.

Before the exam, ease work that raises the ache and note swelling or weakness. Also ask how long soreness may last afterward and when to call.

Sources

1. The ESSKA-ICRS consensus applied the RAND/UCLA appropriateness method to 216 clinical scenarios for intra-articular PRP in knee OA. Only 84 scenarios (38.9%) were rated appropriate, 9 (4.2%) inappropriate and 123 (56.9%) uncertain. PRP was judged appropriate in patients aged 80 or under with KL grade 0-III osteoarthritis AFTER failed conservative non-injective or injective treatment; it was NOT considered appropriate as a first treatment, nor in KL grade IV (bone-on-bone) osteoarthritis, where 91.7% and 87.5% of scenarios respectively were uncertain.

   Kon E, de Girolamo L, Laver L, et al. — Platelet-rich plasma injections for the management of knee osteoarthritis: The ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12320.

2. The 2019 ACR/Arthritis Foundation osteoarthritis guideline makes STRONG recommendations for exercise, weight loss in people with overweight or obesity, self-management programmes, tai chi, cane use, tibiofemoral bracing, topical and oral NSAIDs and intra-articular glucocorticoid injections for knee OA. Its conditional recommendations cover balance exercises, yoga, CBT, acupuncture, thermal modalities, radiofrequency ablation, acetaminophen, duloxetine and tramadol. Anything offered before a course of the strongly recommended options is being offered out of order.

   Kolasinski SL, Neogi T, Hochberg MC, et al. — 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis & Rheumatology, 2020. DOI: 10.1002/art.41142.

3. A systematic review and meta-analysis of adverse events in randomized trials of intra-articular PRP for knee osteoarthritis found PRP associated with mild, transient adverse events - knee pain and swelling - that typically resolve without intervention, and more frequent with LEUKOCYTE-RICH formulations. Leukocyte-poor PRP had a safety profile similar to hyaluronic acid. Knee stiffness was more frequent with PRP than with normal saline (P=.031). No severe adverse events were reported in any group.

   Nakagawa HF, Kim J, Rabinowitz J, et al. — Assessment of adverse events and safety associated with intra-articular platelet-rich plasma injections compared to other injectates for knee osteoarthritis: A systematic review and meta-analysis. PM&R, 2026. DOI: 10.1002/pmrj.70141.

4. PATH-2 randomised 230 adults with acute Achilles tendon rupture managed non-surgically to PRP or a placebo dry-needle injection across 19 UK hospitals, with a central laboratory confirming the PRP was of good quality with the expected growth-factor content. At 24 weeks there was no detectable difference in muscle-tendon function (limb symmetry index 34.7% versus 38.5%; adjusted mean difference -3.9%; 95% CI -10.5% to 2.7%) or in any secondary outcome or adverse-event rate.

   Keene DJ, Alsousou J, Harrison P, et al. — Platelet rich plasma injection for acute Achilles tendon rupture: PATH-2 randomised, placebo controlled, superiority trial. BMJ, 2019. DOI: 10.1136/bmj.l6132.

5. Medicare's national coverage policy covers autologous platelet-rich plasma ONLY for patients with chronic non-healing diabetic, pressure and/or venous wounds, and only within an approved coverage-with-evidence-development clinical study. There is no Medicare national coverage for PRP in osteoarthritis or tendinopathy, which is why these injections are billed to the patient as cash-pay.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2024.

6. The devices used to spin PRP at the point of care are cleared by FDA as clinical centrifuges, product code JQC, a Class I device under 21 CFR 862.2050 - for example the Biomet GPS Platelet Separation Kit (K030555, cleared 2003) and the Harvest SmartPrep2 / SmartPrep Platelet Concentration System (K103340, cleared 2010). That clearance covers the equipment that separates blood. It is not an FDA approval of platelet-rich plasma as a treatment for osteoarthritis, tendinopathy or any other orthopedic condition, and copy must never blur the two.

   U.S. Food and Drug Administration (Center for Devices and Radiological Health) — 510(k) Premarket Notification database and Product Classification: JQC, Centrifuges (Micro, Ultra, Refrigerated) For Clinical Use, 21 CFR 862.2050. FDA accessdata (CDRH device databases), 2003.